Literature DB >> 1603005

Asthma morbidity in Australia: an epidemiological study.

A Bauman1, C A Mitchell, R L Henry, C F Robertson, M J Abramson, E J Comino, M J Hensley, S R Leeder.   

Abstract

OBJECTIVE: To examine the prevalence and management of asthma in adults and children in a population sample in eastern Australia.
SETTING: A random sample of children from 33 primary schools in Sydney, Melbourne, Brisbane, and the Upper Hunter Valley (New South Wales), and their parents.
DESIGN: A cross-sectional analytic survey of 8753 primary school children aged between 5 and 12 years, and their parents (n = 13,945 adults). Asthma prevalence and management practices were determined by parental responses to a questionnaire, and spirometry was performed in children with "probable asthma".
RESULTS: Of 8753 children whose parents responded, the prevalence of current wheeze was 19.5% and diagnosed asthma was 17.1%. Of the children with "probable asthma", 30% had their lung function measured in the previous year, and 6% possessed both a peak flow meter and an action plan for their asthma. Undertreatment was likely, as preventive asthma medications (inhaled corticosteroids or sodium cromoglycate) were used regularly by only 25.5% of these children and by 44.3% of children who had asthma symptoms more than twice per week. Children with the diagnosis of asthma reported higher rates of preventive medication use and ventilatory function measurement than children with frequent symptoms without the diagnosis. In the 13,945 adults, the reported prevalence of asthma was 7%, of whom 39% were using preventive medications, 34% had their ventilatory function assessed in the previous year, and 7% had both a peak flow meter and an asthma action plan.
CONCLUSIONS: The study illustrated the gap between the current level of asthma management in the community and the standards set by the Thoracic Society of Australia and New Zealand. Undertreatment and suboptimal management of asthma remain important problems in Australia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1603005     DOI: 10.5694/j.1326-5377.1992.tb136992.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  9 in total

1.  Prevalence of asthma in adults in Busselton, Western Australia.

Authors:  J K Peat; M Haby; J Spijker; G Berry; A J Woolcock
Journal:  BMJ       Date:  1992-11-28

Review 2.  The cost of asthma: can it be reduced?

Authors:  C M Mellis; J K Peat; A J Woolcock
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

3.  Characterisation of asthma management in the Fallon Community Health Plan from 1988 to 1991.

Authors:  S F Lanes; B M Birmann; A M Walker; A L Sheffer; R A Rosiello; B E Lewis; N A Dreyer
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

4.  Preventable factors in hospital admissions for asthma.

Authors:  G A Ordoñez; P D Phelan; A Olinsky; C F Robertson
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

5.  Incentive spirometry as a means to score breathlessness.

Authors:  Li-Cher Loh; Pek-Ngor Teh; Sree Raman; Pillai Vijayasingham; Tarmizi Thayaparan
Journal:  Malays J Med Sci       Date:  2005-01

Review 6.  Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.

Authors:  R Davis; D McTavish
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

7.  Prevalence of asthma and risk factors among Chinese, Malay, and Indian adults in Singapore.

Authors:  T P Ng; K P Hui; W C Tan
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

8.  Increased wheeze but not bronchial hyperreactivity near power stations.

Authors:  J A Halliday; R L Henry; R G Hankin; M J Hensley
Journal:  J Epidemiol Community Health       Date:  1993-08       Impact factor: 3.710

9.  Changing prevalence of asthma in Australian children.

Authors:  J K Peat; R H van den Berg; W F Green; C M Mellis; S R Leeder; A J Woolcock
Journal:  BMJ       Date:  1994-06-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.